1 ) Kudoh S‚ Azuma A‚ Yamamoto M‚ Izumi T‚ Ando M: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med‚ 157: 1829-1832‚ 1998.
2 ) Fujita S‚Suzuki R‚Sagara N‚Aota A‚ Akashi K‚ Katsunuma T: Three cases of diffuse panbronchiolitis in children with a past history of difficult-to-treat bronchial asthma: A case report from a single medical facility. Allergology International‚ 69: 468-470‚ 2020.
3 )髙栁文貴,西田光宏,山本崇晴:気管支喘息として 5 年間吸入ステロイド薬治療を継続していたびまん 性汎細気管支炎の 1 例.日本小児アレルギー学会 誌,34:566-572,2020.
4 )中田紘一郎:DPBの診断指針改訂と重症度分類策定 厚生省特定疾患びまん性肺疾患調査研究班平成10年 度研究報告書.1999:109-111.
5 )足立雄一,滝沢琢己,二村昌樹,藤澤隆夫:小児喘 息治療・管理ガイドライン 2020.協和企画,東京, 2020.
6 ) Keicho N‚ Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med‚ 1: 119-131‚ 2002.
7 ) Takeyama K‚ Shimizu Y‚ Ishii M‚ Hara H‚ Kondo M‚ Tamaoki J: Coexistence of diffuse panbronchiolitis and asthma: reciprocity of neutrophilic and eosinophilic inflammation. Respirol Case Rep‚ 5: e00232‚ 2017.
8 ) Matsuno O‚ Ueno K‚Hayama Y‚ Honda H‚ Yamane H‚ Saeki Y: Deterioration of asthma in a patient with diffuse panbronchiolitis (DPB) after macrolide therapy. J Asthma‚ 47: 486-488‚ 2010.